Sharechat Logo

NZ Super Fund's Matt Whineray appointed CEO

Tuesday 19th June 2018

Text too small?

The New Zealand Superannuation Fund's board has appointed Matt Whineray as chief executive, a role he has been acting in since March after Adrian Orr left the job.

Whineray, who was previously the fund's chief investment officer, first joined the organisation in 2008. His appointment will be effective from July 1.

The fund said it had undergone a global, publicly-advertised search process for a new CEO, and Whineray was "the stand-out candidate amongst a high-quality field of international applicants."

"He has been instrumental in the Guardians’ successes over the last decade and is recognised globally as a leader in institutional investment. The board has the utmost confidence in his leadership ability, intelligence and integrity," said chair Catherine Savage. "The board looks forward to seeing the NZ Super Fund continue to exemplify investment best practice and create value for taxpayers."

Whineray will oversee the $37.9 billion fund, which has had a 10.5 percent average annual rate of return since inception, before tax and after costs and a workforce of approximately 140 people, including 55 investment professionals. While 86 percent of the fund is invested globally, it has $5 billion invested in New Zealand.

(BusinessDesk)



  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors